Jin-ji L. Yang
106 Zhongshan 2nd Road
Guangzhou, 510080, China
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 182 publications
FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.
Journal: Science translational medicine
Published: August 26, 2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics.
Journal: Journal of translational medicine
Published: May 07, 2026
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.
Journal: The Journal of international medical research
Published: December 16, 2025
Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer.
Journal: Journal of translational medicine
Published: October 29, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.
Journal: Journal for immunotherapy of cancer
Published: October 26, 2025
Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 02, 2025
Response to Letter to the Editor: "Refining Immunochemoradiotherapy for Patients With NSCLC and Brain Metastases: Insights on Biomarkers, Neuroprotection, and Global Applicability".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 27, 2025
Development and validation of the rapid health aging assessment scale for the Chinese population
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: July 15, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
Journal: The Lancet. Oncology
Published: July 02, 2025
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Journal: Nature communications
Published: June 21, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Journal: Translational lung cancer research
Published: June 19, 2025
Last Updated: 09/26/2026